Continuous Daily Dosing of Sunitinib in Patients with Metastatic Renal Cell Cancer

Publisher： Karger

E-ISSN： 2296-5262|31|8-9|432-433

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.8-9, 2008-08, pp. : 432-433

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Continuous Therapy with Sunitinib in Patients with Metastatic Renal Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 31, Iss. 8-9, 2008-07 ,pp. : 485-485

Karger

Access to resources Recommend Favorite

The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer

By  

Urologia Internationalis, Vol. 86, Iss. 1, 2010-10 ,pp. : 53-59

Karger

Access to resources Recommend Favorite

Relationships between the Effect of Sunitinib and Immature Blood Vessels in Metastatic Renal Cell Cancer

By  

Urologia Internationalis, Vol. 94, Iss. 2, 2015-0 ,pp. : 137-143

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial

By  

Oncology, Vol. 88, Iss. 5, 2015-01 ,pp. : 273-280

Karger

Access to resources Recommend Favorite

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3435-3443

John Wiley & Sons Inc

Access to resources Recommend Favorite